Technology News and Research

RSS

Discovery of compounds that selectively kills cancer stem cells

The cancer stem cells that drive tumor growth and resist chemotherapies and radiation treatments that kill other cancer cells aren't invincible after all. Researchers reporting online on August 13th in the journal Cell, a Cell Press publication, have discovered the first compound that targets those cancer stem cells directly.

13 Aug 2009

Scientists grow new blood vessels to combat heart disease

Although open-heart surgery is a frequent treatment for heart disease, it remains extremely dangerous. Now groundbreaking research from Dr. Britta Hardy of Tel Aviv University's Sackler School of Medicine has shown the potential for an injected protein to regrow blood vessels in the human heart ― eliminating the need for risky surgery altogether.

13 Aug 2009

High caffeine consumption, more headaches?

People who consume high amounts of caffeine each day are more likely to suffer occasional headaches than those with low caffeine consumption, a team of researchers at the Norwegian University of Science and Technology (NTNU) reports in a study recently published in the Journal of Headache Pain.

13 Aug 2009

Nfocus Neuromedical obtains CE approval for vascular reconstruction device

Nfocus Neuromedical Inc. announced today that its CardioVasc Advantage Vascular Reconstruction Device has been granted CE Mark approval by the European Notified Body, G-Med.

13 Aug 2009

MRI increases chances of more extensive surgery over conservative approaches in breast cancer diagnosis

A new review says using magnetic resonance imaging (MRI) before surgery to assess the extent of early breast cancer has not been shown to improve surgical planning, reduce follow-up surgery, or reduce the risk of local recurrences.

13 Aug 2009

Medical imaging: The good, the bad and the ugly

In the political minefield of healthcare reform, medical imaging has emerged as a microcosm of this contentious debate. Congress has been charged with a high stakes, high wire balancing act: to create a bill preserving quality and access while trimming unethical and unnecessary spending. Medical imaging represents such a challenge, with its undeniable benefits tainted by inappropriate use.

13 Aug 2009

Clever biochemical strategy enables bacteria to move freely and colonize host

A team of researchers from Boston University, Harvard Medical School and Massachusetts Institute of Technology recently made a discovery that changes a long held paradigm about how bacteria move through soft gels.

13 Aug 2009

Westaim announces Q2 2009 financials

The Westaim Corporation announced today that for the quarter ended June 30, 2009, it recorded a net loss of $1.3 million, or 1 cent per share, on revenues of $5.8 million compared to a net loss of $3.0 million, or 3 cents per share, on revenues of $4.8 million in the same quarter for the previous year.

13 Aug 2009

Promising new treatment target for Kennedy's disease

New research with transgenic mice reveals that a therapy directed at the muscle significantly improves disease symptoms of a genetic disorder characterized by destruction of the neurons that control movement. The study, published by Cell Press in the August 13th issue of the journal Neuron, highlights a promising new treatment for this currently incurable and nontreatable neurodegenerative disorder.

12 Aug 2009

Pacific Biosciences raises additional $68 million in financing

Pacific Biosciences, a private company pioneering the development of a transformative DNA sequencing technology, announced today it has raised an additional $68 million in financing.

12 Aug 2009

Cryolife receives 510(k) clearance from FDA for CryoPatch SG pulmonary human cardiac patch

CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CryoPatch((R)) SG pulmonary human cardiac patch.

12 Aug 2009

Cambridge Heart reports Q2 financial for 2009

Cambridge Heart, Inc. (OTCBB-CAMH), today reported results for its second quarter ended June 30, 2009. The following financial and strategic items highlight the Company’s activity for the second quarter.

12 Aug 2009

Harvard receives $10 million to develop small-scale mobile robotic devices

A multidisciplinary team of computer scientists, engineers, and biologists at Harvard received a $10 million National Science Foundation (NSF) Expeditions in Computing grant to fund the development of small-scale mobile robotic devices.

12 Aug 2009

Emdeon opens for trading today on NYSE

Emdeon Inc. opened for trading today on the New York Stock Exchange under the ticker symbol “EM” after its successful initial public offering in which it raised $367 million in gross proceeds. Headquartered in Nashville, Tenn., Emdeon is the 13th IPO by an operating company, including non-U.S. companies, and the 10th U.S. domestic IPO to list on the New York Stock Exchange this year.

12 Aug 2009

New understanding on basic cellular mechanisms responsible speech processing

Researchers from the Hebrew University of Jerusalem have succeeded for the first time in devising a model that describes and identifies a basic cellular mechanism that enables networks of neurons to efficiently decode speech in changing conditions.

12 Aug 2009

IBM to deliver advanced analytic solutions to public sector clients

IBM (NYSE: IBM) today announced the creation of a new practice focused on delivering advanced analytic solutions to public sector clients. IBM will expand its work with federal, state and local government organizations, as well as in fast-growing markets such as healthcare and education.

12 Aug 2009

Potential new treatment for drug resistant brain tumors

Dr. Karen Newell, Ph. D., the lead researcher for bio technology company Viral Genetics (Pink Sheets: VRAL), will address the 4th Annual Aspen Symposium on Brain Tumor Immuno- and Stem Cell Therapy. Her presentation will highlight the potential for combining chemotherapy with compounds that interfere with the ability of brain tumor cells to generate the energy needed to repair chemotherapy induced DNA damage.

12 Aug 2009

Retrovirox receives another NIH grant for novel inhibitors of HIV entry

RetroVirox, Inc., a biotechnology company specializing in the development of novel antivirals, announced today that it has received a grant award of $296,875 from the National Institute of Allergy and Infectious Disease (NIAID), of the National Institutes of Health (NIH). This is the second award to RetroVirox from the NIH in less than six months. In March 2009 the company received its first grant to develop novel inhibitors of HIV entry.

12 Aug 2009

New tool for virtual surgery simulates blood flow - helps plan child's delicate heart surgery

Researchers at the Georgia Institute of Technology, collaborating with pediatric cardiologists and surgeons at The Children's Hospital of Philadelphia, have developed a tool for virtual surgery that allows heart surgeons to view the predicted effects of different surgical approaches. By manipulating three-dimensional cardiac magnetic resonance images of a patient's specific anatomy, physicians can compare how alternative approaches affect blood flow and expected outcomes, and can select the best approach for each patient before entering the operating room.

12 Aug 2009

Alticor and Metagenics enters into joint venture agreement

Alticor and Metagenics today announced that they have entered into a joint venture agreement. Under the terms of the agreement, Alticor will obtain a substantial ownership interest in Metagenics, and the current Metagenics shareholders will continue to retain a significant interest in the company. The agreement is subject to customary closing conditions, including approval by Metagenics shareholders and antitrust clearance.

12 Aug 2009